1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68604F2601FF92A268525835A00525867
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/8604F2601FF92A268525835A00525867
18
19
2054.227.157.163
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Managed Care Managed Care Organizations and Winning Practices

Best Practices in Formulary Success: Key Payer Responsibilities and Pharma Support

ID: 5537


Features:

5 Info Graphics

12 Data Graphics

90+ Metrics

6 Narratives


Pages/Slides: 22


Published: 2018


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Best Practices in Formulary Success: Key Payer Responsibilities and Pharma Support"

STUDY OVERVIEW

Pharmaceutical field medical team (FMT) interactions with payers have risen in importance as the influence of payers has dramatically increased. As the healthcare market shifts to a value-based system, a new product’s position on a formulary is now as important as its reception among prescribers and KOLs. Recognizing this trend, pharma is paying more attention to the roles and responsibilities of payers, especially how they relate to formulary decisions.

This study explores the key responsibilities/activities of payers in leadership positions (pharmacy directors, medical directors, etc.) and how pharma supports these payer activities.

KEY TOPICS

  • Executive Summary: Methodology, Participants, & Key Findings
  • Primary Responsibilities and Payer Support

KEY METRICS

  • How much time do you spend on reviewing clinical data and making recommendations & how do pharma companies help you in conducting this activity?
  • How much time do you spend on developing formulary policy decisions & how do pharma companies help you in conducting this activity?
  • How much time do you spend on ensuring compliance with healthcare delivery programs & how do pharma companies help you in conducting this activity?
  • How much time do you spend on developing or implementing pathway decisions & how do pharma companies help you in conducting this activity?
  • How much time do you spend on modifying programs due to changes in law & how do pharma companies help you in conducting this activity?
SAMPLE KEY FINDINGS
  • Respondents representing the two principal types of payers in this study, MCOs and PBMs, share the same two principal responsibilities and said they spend a significant amount of their time on them:
      • Reviewing clinical data and making recommendations
      • Developing formulary policy decisions

METHODOLOGY

This study engaged a total of 23 formulary leaders from at least 16 managed care organizations. Medical directors represented more than 40% of the respondents.

Industries Profiled:
Insurance; Health Care; Medical


Companies Profiled:
Anthem; UnityPoint Health; HCA; St. Joseph's Health; Kaiser Permanente; Ascension; Express Scripts; Cleveland Clinic; Inc.; University Hospitals; WellSpan Health; Aetna; CVS Health; Humana; DaVita; Tenet Healthcare ; MedImpact


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.